Sunshine Biopharma, Inc. reported its financial results for the second quarter of 2025, revealing a revenue of $9.41 million, a slight increase from $9.30 million in the same period last year. For the first half of 2025, the company generated $18.31 million in revenue, up 8.7% from $16.84 million in the first half of 2024. The increase in revenue is attributed to enhanced marketing efforts. However, the company also reported a net loss of $1.77 million for the second quarter, compared to a loss of $494,300 in the prior year, and a net loss of $2.95 million for the first half of 2025, compared to a loss of $1.78 million in the same period of 2024.
The company's gross profit for the second quarter increased to $3.42 million, up from $2.36 million a year earlier, reflecting a decrease in the cost of sales from 74.7% to 63.6% of revenue. However, general and administrative expenses rose significantly to $5.48 million in the second quarter, compared to $3.62 million in the same quarter of 2024. This increase was primarily due to a $1.06 million impairment of intangible assets and higher consulting fees related to warrant exercises. The total loss from operations for the second quarter was $2.05 million, compared to a loss of $1.27 million in the same quarter of the previous year.
Operationally, Sunshine Biopharma continues to focus on its two wholly owned subsidiaries, Nora Pharma and Sunshine Biopharma Canada, which collectively offer 74 generic prescription drugs in Canada. The company is also developing proprietary drugs, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections. As of June 30, 2025, the company reported total assets of $31.97 million, an increase from $30.56 million at the end of 2024, while total liabilities decreased to $6.28 million from $7.06 million.
In terms of strategic developments, Sunshine Biopharma completed a registered direct offering in April 2025, raising approximately $1.83 million in net proceeds. The company also reported a significant change in its employee headcount, with new hires contributing to increased salary expenses. The company is currently generating approximately $9.4 million in revenue per quarter and is focused on reducing its cost of goods sold from 65% to 60% to achieve breakeven. Looking ahead, Sunshine Biopharma believes its existing cash and generated sales will be sufficient to fund operations for the next 24 months, although it acknowledges the need for additional capital for future research and development activities.
About Sunshine Biopharma, Inc
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.